Generic placeholder image

Current Drug Discovery Technologies

Author(s): Shital Patil*, Vrushali Randive, Indrani Mahadik and Kalyani Asgaonkar

DOI: 10.2174/0115701638263890231027071518

DownloadDownload PDF Flyer Cite As
Design, In Silico Molecular Docking, and ADMET Prediction of Amide Derivatives of Chalcone Nucleus as EGFR Inhibitors for the Treatment of Cancer

Article ID: e021123223070 Pages: 11

  • * (Excluding Mailing and Handling)

Abstract

Background: Cancer is a devastating disease. Many studies have shown that the primary causes of the aggressive and resistant types of cancer are the overexpression of receptors and growth factors, activation of oncogenes, and the inactivation of tumour suppressor genes. One such receptor is the epidermal growth factor receptor (EGFR), which is used as a drug target for the treatment of cancer.

Objective:This study aimed to develop the new chemical entities of amide derivatives of chalcone as EGFR inhibitors using structure-activity relationship (SAR) studies, molecular docking, and ADMET (absorption, distribution, metabolism, excretion, and toxicity) studies.

Method: New chemical entities (NCE) were designed based on literature findings. The Schrodinger 13.4 software was used for the molecular docking study. While Quickprop and Pro Tox-II online tools were used for ADME and toxicity prediction, respectively.

Result: In this work, all compounds were subjected to an in-silico ADMET analysis. After pharmacokinetic and toxicity profile predictions, the molecules were further analysed by molecular docking. As a result of molecular docking, molecules AC9 and AC19 showed comparable docking scores compared to standard Afatinib.

Conclusion: Molecules AC9 and AC19 showed good docking scores and a promising ADMET profile. In the future, these derivatives can be further evaluated for wet lab studies and determination of their biological activity.

Graphical Abstract

[1]
Seshacharyulu P, Ponnusamy MP, Haridas D, Jain M, Ganti AK, Batra SK. Targeting the EGFR signaling pathway in cancer therapy. Expert Opin Ther Targets 2012; 16(1): 15-31.
[http://dx.doi.org/10.1517/14728222.2011.648617] [PMID: 22239438]
[2]
Worldwide cancer data. Available from: https://www.wcrf.org/cancer-trends/worldwide-cancer-data (Accessed on 11 Feb 2023)
[3]
Types of Cancer Treatment. Available from: https://www.cancer.gov/about-cancer/treatment/types (Accessed on 11 Feb 2023)
[4]
Solassol I, Pinguet F, Quantin X. FDA- and EMA-approved tyrosine kinase inhibitors in advanced egfr-mutated non-small cell lung cancer: safety, tolerability, plasma concentration monitoring, and management. Biomolecules 2019; 9(11): 668.
[http://dx.doi.org/10.3390/biom9110668] [PMID: 31671561]
[5]
Liederer BM, Friess T, Shames D, Wright M, Hop CECA. Reversible versus irreversible egfr tyrosine-kinase inhibitors for non-small-cell lung cancer (NSCLC): A preclinical and pharmacokinetic comparison. Adv NSCLC 2015; 26(1): 129.
[6]
Tiwari A, Bendi A, Bhathiwal AS. An overview on synthesis and biological activity of chalcone derived pyrazolines. ChemistrySelect 2021; 6(45): 12757-95.
[http://dx.doi.org/10.1002/slct.202103779]
[7]
Singh S, Sharma B, Kanwar SS, Kumar A. Lead phytochemicals for anticancer drug development. Front Plant Sci 2016; 7: 1667.
[http://dx.doi.org/10.3389/fpls.2016.01667] [PMID: 27877185]
[8]
Božić DD, Milenković M, Ivković B, Ćirković I. Antibacterial activity of three newly-synthesized chalcones & synergism with antibiotics against clinical isolates of methicillin-resistant Staphylococcus aureus. Indian J Med Res 2014; 140(1): 130-7.
[PMID: 25222788]
[9]
Nielsen SF, Boesen T, Larsen M, Schønning K, Kromann H. Antibacterial chalcones––bioisosteric replacement of the 4′-hydroxy group. Bioorg Med Chem 2004; 12(11): 3047-54.
[http://dx.doi.org/10.1016/j.bmc.2004.03.071] [PMID: 15142563]
[10]
Cheng P, Yang L, Huang X, Wang X, Gong M. Chalcone hybrids and their antimalarial activity. Arch Pharm 2020; 353(4)1900350
[http://dx.doi.org/10.1002/ardp.201900350] [PMID: 32003489]
[11]
Liu M, Wilairat P, Go ML. Antimalarial alkoxylated and hydroxylated chalcones [corrected]: Structure-activity relationship analysis. J Med Chem 2001; 44(25): 4443-52.
[http://dx.doi.org/10.1021/jm0101747] [PMID: 11728189]
[12]
Zhang HJ, Qian Y, Zhu DD, Yang XG, Zhu HL. Synthesis, molecular modeling and biological evaluation of chalcone thiosemicarbazide derivatives as novel anticancer agents. Eur J Med Chem 2011; 46(9): 4702-8.
[http://dx.doi.org/10.1016/j.ejmech.2011.07.016] [PMID: 21816517]
[13]
Zhuang C, Zhang W, Sheng C, Zhang W, Xing C, Miao Z. Chalcone: A privileged structure in medicinal chemistry. Chem Rev 2017; 117(12): 7762-810.
[http://dx.doi.org/10.1021/acs.chemrev.7b00020] [PMID: 28488435]
[14]
Reddy P, Reddy MBM, Reddy R, Chhajed S, Gupta PP. Molecular docking, PKPD, and assessment of toxicity of few chalcone analogues as EGFR inhibitor in search of anticancer agents. Struct Chem 2020; 31(6): 2249-55.
[http://dx.doi.org/10.1007/s11224-020-01571-3]
[15]
Afatinib. Available from: https://go.drugbank.com/drugs/DB08916 (Accessed on 20/09/2023)
[16]
Kwak EL, Sordella R, Bell DW, et al. Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib. Proc Natl Acad Sci 2005; 102(12): 7665-0.
[http://dx.doi.org/10.1073/pnas.0502860102M]
[17]
Tekale S, Mashele S, Pooe O, Thore S, Kendrekar P, Pawar R. Biological role of chalcones in medicinal chemistry. In: Claborn D, Bhattacharya S, Roy S, Eds. Vector-Borne Diseases - Recent Developments in Epidemiology and Control. IntechOpen 2020.
[http://dx.doi.org/10.5772/intechopen.91626]
[18]
Mukesh B, Rakesh K. Molecular docking: A review. IJRAP 2011; 2: 1746-51.
[19]
Guedes IA, de Magalhães CS, Dardenne LE. Receptor-ligand molecular docking. Biophys Rev 2014; 6(1): 75-87.
[http://dx.doi.org/10.1007/s12551-013-0130-2] [PMID: 28509958]
[20]
Yang EB, Guo YJ, Zhang K, Chen YZ, Mack P. Inhibition of epidermal growth factor receptor tyrosine kinase by chalcone derivatives. Biochim Biophys Acta Protein Struct Mol Enzymol 2001; 1550(2): 144-52.
[http://dx.doi.org/10.1016/S0167-4838(01)00276-X] [PMID: 11755203]
[21]
Dias TA, Duarte CL, Lima CF, Proença MF, Pereira-Wilson C. Superior anticancer activity of halogenated chalcones and flavonols over the natural flavonol quercetin. Eur J Med Chem 2013; 65: 500-10.
[http://dx.doi.org/10.1016/j.ejmech.2013.04.064] [PMID: 23771043]
[22]
Madhavi S, Sreenivasulu R, Yazala JP, Raju RR. Synthesis of chalcone incorporated quinazoline derivatives as anticancer agents. Saudi Pharm J 2017; 25(2): 275-9.
[http://dx.doi.org/10.1016/j.jsps.2016.06.005] [PMID: 28344479]
[23]
Chhajed SS, Sonawane SS, Upasani CD, Kshirsagar SJ, Gupta PP. Design, synthesis and molecular modeling studies of few chalcone analogues of benzimidazole for epidermal growth factor receptor inhibitor in search of useful anticancer agent. Comput Biol Chem 2016; 61: 138-44.
[http://dx.doi.org/10.1016/j.compbiolchem.2016.02.001] [PMID: 26878127]
[24]
Mphahlele M, Maluleka M, Parbhoo N, Malindisa S. Synthesis, evaluation for cytotoxicity and molecular docking studies of benzo[c]furan-chalcones for potential to inhibit tubulin polymerization and/or EGFR-tyrosine kinase phosphorylation. Int J Mol Sci 2018; 19(9): 2552-69.
[http://dx.doi.org/10.3390/ijms19092552] [PMID: 30154363]
[25]
Sivanandan S, Jain K, Plakkal N, et al. Issues, challenges, and the way forward in conducting clinical trials among neonates: Investigators’ perspective. J Perinatol 2019; 39(S1): 20-30.
[http://dx.doi.org/10.1038/s41372-019-0469-8] [PMID: 31485015]
[26]
The Advantages of ADME Properties Prediction. Available from: https://www.schrodinger.com/products/qikprop (Accessed on 17 Feb 2023)
[27]
Benet LZ, Hosey CM, Ursu O, Oprea TI. BDDCS, the Rule of 5 and drugability. Adv Drug Deliv Rev 2016; 101: 89-98.
[http://dx.doi.org/10.1016/j.addr.2016.05.007] [PMID: 27182629]
[28]
Banerjee P, Eckert AO, Schrey AK, Preissner R. ProTox-II: A webserver for the prediction of toxicity of chemicals. Nucleic Acids Res 2018; 46(W1)W257-63
[http://dx.doi.org/10.1093/nar/gky318] [PMID: 29718510]
[29]
Banerjee P, Dehnbostel FO, Preissner R. Prediction is a balancing act: Importance of sampling methods to balance sensitivity and specificity of predictive models based on imbalanced chemical data sets. Front Chem 2018; 6: 362.
[http://dx.doi.org/10.3389/fchem.2018.00362] [PMID: 30271769]
[30]
Drwal MN, Banerjee P, Dunkel M, Wettig MR, Preissner R. ProTox: A web server for the in silico prediction of rodent oral toxicity. Nucleic Acids Res 2014; 42(W1): W53-8.
[http://dx.doi.org/10.1093/nar/gku401]
[31]
Ligprep. Available from: https://www.schrodinger.com/products/ligprep (Accessed on 6 Mar 2023)
[32]
Stamos J, Sliwkowski MX, Eigenbrot C. Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor. J Biol Chem 2002; 277(48): 46265-72.
[http://dx.doi.org/10.1074/jbc.M207135200] [PMID: 12196540]
[33]
Harder E, Damm W, Maple J, et al. OPLS3: A force field providing broad coverage of drug-like small molecules and proteins. J Chem Theory Comput 2016; 12(1): 281-96.
[http://dx.doi.org/10.1021/acs.jctc.5b00864] [PMID: 26584231]
[34]
Friesner RA, Murphy RB, Repasky MP, et al. Extra precision glide: docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes. J Med Chem 2006; 49(21): 6177-96.
[http://dx.doi.org/10.1021/jm051256o] [PMID: 17034125]
[35]
Halgren TA, Murphy RB, Friesner RA, et al. Glide: A new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening. J Med Chem 2004; 47(7): 1750-9.
[http://dx.doi.org/10.1021/jm030644s] [PMID: 15027866]
[36]
Friesner RA, Banks JL, Murphy RB, et al. Glide: A new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. J Med Chem 2004; 47(7): 1739-49.
[http://dx.doi.org/10.1021/jm0306430] [PMID: 15027865]
[37]
Docking and Scoring. Available from: https://www.schrodinger.com/science-articles/docking-and-scoring (Accessed on 24 Mar 2023)
[38]
Ahmed FF, Abd El-Hafeez AA, Abbas SH, Abdelhamid D, Abdel-Aziz M. New 1,2,4-triazole-Chalcone hybrids induce Caspase-3 dependent apoptosis in A549 human lung adenocarcinoma cells. Eur J Med Chem 2018; 151: 705-22.
[http://dx.doi.org/10.1016/j.ejmech.2018.03.073] [PMID: 29660690]
[39]
Mohassab AM, Hassan HA, Abdelhamid D, et al. Design and synthesis of novel quinoline/chalcone/1,2,4-triazole hybrids as potent antiproliferative agent targeting EGFR and BRAFV600E kinases. Bioorg Chem 2021; 106104510
[http://dx.doi.org/10.1016/j.bioorg.2020.104510] [PMID: 33279248]
[40]
Fathi MAA, Abd El-Hafeez AA, Abdelhamid D, Abbas SH, Montano MM, Abdel-Aziz M. 1,3,4-oxadiazole/chalcone hybrids: Design, synthesis, and inhibition of leukemia cell growth and EGFR, Src, IL-6 and STAT3 activities. Bioorg Chem 2019; 84: 150-63.
[http://dx.doi.org/10.1016/j.bioorg.2018.11.032] [PMID: 30502626]
[41]
Abou-Zied HA, Youssif BGM, Mohamed MFA, Hayallah AM, Abdel-Aziz M. EGFR inhibitors and apoptotic inducers: Design, synthesis, anticancer activity and docking studies of novel xanthine derivatives carrying chalcone moiety as hybrid molecules. Bioorg Chem 2019; 89102997
[http://dx.doi.org/10.1016/j.bioorg.2019.102997] [PMID: 31136902]
[42]
Anwar C, Prasetyo YD, Matsjeh S, Haryadi W, Sholikhah EN, Nendrowati N. Synthesis of chalcone derivatives and their in vitro anticancer test against breast (T47D) and Colon (WiDr) cancer cell line. Ind J Chem 2018; 18(1): 102.
[http://dx.doi.org/10.22146/ijc.26864]
[43]
Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings 1PII of original article: S0169-409X(96)00423-1. Adv Drug Deliv Rev 2001; 46(1-3): 3-26.
[http://dx.doi.org/10.1016/S0169-409X(00)00129-0] [PMID: 11259830]
[44]
Knowledge Base. Available from: https://www.schrodinger.com/kb/730 (Accessed on 5th April 2023)
[45]
Reddi RN, Resnick E, Rogel A, et al. Tunable methacrylamides for covalent ligand directed release chemistry. J Am Chem Soc 2021; 143(13): 4979-92.
[http://dx.doi.org/10.1021/jacs.0c10644] [PMID: 33761747]